Procoagulant status was modeled in outbred female mice by single injection of cisplatin in a maximum tolerated dose and hemostasis parameters monitored over 30 days by methods of coagulogram and low-frequency piezothromboelastography (global test). Monitoring revealed waveform changes in the hemostatic potential: the structural and chronometric hypercoagulation recorded starting from the first day and attaining its maximum on days 5-7 was followed by hypocoagulation and returned to normocoagulation on day 30. This pattern reflects prolonged effect of cisplatin: formation of severe dysfunction of the endothelium providing the main anticoagulant pool of hemostasis (day 1) aggravated by disturbances of the plastic functions of the liver (days 15-20), and recovery (days 20-30).
Similar content being viewed by others
References
Abdol Razak NB, Jones G, Bhandari M, Berndt M. C, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10(10). pii: E380. https://doi.org/10.3390/cancers10100380
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 2014;740:364-378.
Francescato HDC, Almeida LF, Reis NG, Faleiros CM, Papoti M, Costa RS, Coimbra TM. Previous exercise effects in cisplatin-induced renal lesions in rats. Kidney Blood Press. Res. 2018;43(2):582-593.
Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J. Thromb. Haemost. 2007;5(12):2445-2452.
Li W, Lam MS, Birkeland A, Riffel A, Montana L, Sullivan ME, Post JM. Cell-based assays for profiling activity and safety properties of cancer drugs.. J. Pharmacol. Toxicol. Methods. 2006;54(3):313-319.
Nasser NJ, Fox J, Agbarya A. Potential mechanisms of cancerrelated hypercoagulability. Cancers (Basel). 2020;12(3). pii: E566. https://doi.org/10.3390/cancers12030566
Oppelt P, Betbadal A, Nayak L. Approach to chemotherapyassociated thrombosis. Vasc. Med. 2015;20(2):153-161.
Udut VV, Solov’еv MA, Karchagina OS, Borodulina EV, Tyutrin II, Klimenkova VF, Malyugin EF, Turenko AV. Global tests in evaluation of the function of pro and anticoagulant systems: Present and future. Bulletin of Experimental Biology and Medicine. 2015;159;(2):205-208.
Xu Y, Ma H, Shao J, Wu J, Zhou L, Zhang Z, Wang Y, Huang Z, Ren J, Liu S, Chen X, Han J. A role for tubular necroptosis in cisplatin-induced AKI. J. Am. Soc. Nephrol. 2015;26(11):2647-2658.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 170, No. 7, pp. 21-25, July, 2020
Rights and permissions
About this article
Cite this article
Filonova, M.V., Fedorova, E.P., Churin, A.A. et al. Changes in Hemostasis System in Outbred Female Mice with Cisplatin-Induced Procoagulant Status. Bull Exp Biol Med 170, 15–18 (2020). https://doi.org/10.1007/s10517-020-04995-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-020-04995-3